Whole body vibration compared to conventional physiotherapy in patients with gonarthrosis: A protocol for a randomized, controlled study

BMC Musculoskeletal Disorders

Volumn 11, Issue , 2010, Pages

  Stein, Gregor ^a   Knoell, Peter ^a   Faymonville, Christoph ^a   Kaulhausen, Thomas ^a   Siewe, Jan ^a   Otto, Christina ^a   Eysel, Peer ^a   Zarghooni, Kourosh ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTHRITIS; ARTICLE; CANADA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXERCISE; FOLLOW UP; FORCE; HUMAN; JOINT FUNCTION; KNEE OSTEOARTHRITIS; MOBILIZATION; OUTCOME ASSESSMENT; PHYSIOTHERAPY; RANDOMIZED CONTROLLED TRIAL; WHOLE BODY VIBRATION; CLINICAL PROTOCOL; COMPARATIVE STUDY; DISABILITY; FEMALE; HIP OSTEOARTHRITIS; HOSPITALIZATION; MALE; METHODOLOGY; MIDDLE AGED; NEUROLOGIC DISEASE; PATHOPHYSIOLOGY; STANDARD; STATISTICS; VIBRATION; WALKING DIFFICULTY;

ADULT; AGED; AGED, 80 AND OVER; CLINICAL PROTOCOLS; DISABILITY EVALUATION; FEMALE; GAIT DISORDERS, NEUROLOGIC; HUMANS; MALE; MIDDLE AGED; MOBILITY LIMITATION; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; OUTCOME ASSESSMENT (HEALTH CARE); PHYSICAL THERAPY MODALITIES; SEVERITY OF ILLNESS INDEX; VIBRATION;

EID: 77954584247     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-11-128     Document Type: Article

References (26)

1. The role of viscosupplementation with hylan G-F 20 (Synvisc) in the treatment of osteoarthritis of the knee: a Canadian multicenter trial comparing hylan G-F 20 alone, hylan G-F 20 with non-steroidal anti-inflammatory drugs (NSAIDs) and NSAIDs alone. ME Adams MH Atkinson AJ Lussier JI Schulz KA Siminovitch JP Wade M Zummer, Osteoarthritis Cartilage 1995 3 4 213 25 10.1016/S1063-4584(05)80013-5 8689457
2. The pathophysiology of osteoarthritis and the implication of the use of hyaluronan and hylan as therapeutic agents in viscosupplementation. JP Pelletier J Martel-Pelletier, J Rheumatol Suppl 1993 39 19 24 8410880
3. The role of elastoviscosity in the efficacy of viscosupplementation for osteoarthritis of the knee: a comparison of hylan G-F 20 and a lower-molecular-weight hyaluronan. M Wobig G Bach P Beks A Dickhut J Runzheimer G Schwieger G Vetter E Balazs, Clin Ther 1999 21 9 1549 62 10.1016/S0149- 2918(00)80010-7 10509850
4. Epidemiology of musculoskeletal impairments and associated disability. LS Cunningham JL Kelsey, Am J Public Health 1984 74 6 574 9 10.2105/AJPH.74.6.574 6232862
5. Estimates of the prevalence of rheumatic diseases in the population of Tecumseh, Michigan, 1959-60. WM Mikkelsen HJ Dodge IF Duff H Kato, J Chronic Dis 1967 20 6 351 69 10.1016/0021-9681(67)90009-4 5298089
6. Epidemiology of osteoarthritis: Zoetermeer survey. Comparison of radiological osteoarthritis in a Dutch population with that in 10 other populations. JL van Saase LK van Romunde A Cats JP Vandenbroucke HA Valkenburg, Ann Rheum Dis 1989 48 4 271 80 10.1136/ard.48.4.271 2712610
7. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. DT Felson Y Zhang, Arthritis Rheum 1998 41 8 1343 55 10.1002/1529-0131(199808)41:8<1343:AID-ART3>3.0.CO;2-9 9704632
8. Incidence of symptomatic hand, hip, and knee osteoarthritis among patients in a health maintenance organization. SA Oliveria DT Felson JI Reed PA Cirillo AM Walker, Arthritis Rheum 1995 38 8 1134 41 10.1002/art.1780380817 7639811
9. Treatment of knee joint arthritis in the middle-aged patient. J Duchow D Kohn, Orthopade 2003 32 10 920 29 quiz 30 10.1007/s00132-003-0566-3 14579028
10. Molecular principles of induction and progression of arthrosis. O Pullig D Pfander B Swoboda, Orthopade 2001 30 11 825 33 10.1007/s001320170018 11766626
11. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. R Altman E Asch D Bloch G Bole D Borenstein K Brandt W Christy TD Cooke R Greenwald M Hochberg, Arthritis Rheum 1986 29 8 1039 49 10.1002/art.1780290816 3741515
12. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. ACR, Arthritis Rheum 2000 43 9 1905 15 American College of Rheumatology Subcommittee on Osteoarthritis Guidelines 10.1002/1529- 0131(200009)43:9<1905:AID-ANR1>3.0.CO;2-P 11014340
13. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee.American College of Rheumatology. MC Hochberg RD Altman KD Brandt BM Clark PA Dieppe MR Griffin RW Moskowitz TJ Schnitzer, Arthritis Rheum 1995 38 11 1541 6 10.1002/art.1780381104 7488273
14. Drug therapy of arthrosis. J Steinmeyer, Orthopade 2001 30 11 856 65 10.1007/s001320170022 11766630
15. The role of proprioceptive deficits, ligamentous laxity, and malalignment in development and progression of knee osteoarthritis. L Sharma, J Rheumatol Suppl 2004 70 87 92 15132362
16. Acute and cumulative effects of different times of recovery from whole body vibration exposure on muscle performance. ME Da Silva-Grigoletto DM Vaamonde E Castillo MS Poblador JM Garcia-Manso JL Lancho, J Strength Cond Res 2009 23 7 2073 82 19855333
17. Effects of whole-body vibration exercise on lower-extremity muscle strength and power in an older population: a randomized clinical trial. SS Rees AJ Murphy ML Watsford, Phys Ther 2008 88 4 462 70 18218826
18. Vibration therapy. F Rauch, Dev Med Child Neurol 2009 51 Suppl 4 166 8 10.1111/j.1469-8749.2009.03418.x 19740225
19. Effect of whole body vibration exercise on muscle strength and proprioception in females with knee osteoarthritis. T Trans J Aaboe M Henriksen R Christensen H Bliddal H Lund, Knee 2009 16 4 256 61 10.1016/j.knee.2008.11.014 19147365
20. WOMAC: a 20-year experiential review of a patient-centered self-reported health status questionnaire. N Bellamy, J Rheumatol 2002 29 12 2473 6 12465137
21. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. N Bellamy WW Buchanan CH Goldsmith J Campbell LW Stitt, J Rheumatol 1988 15 12 1833 40 3068365
22. Committee for proprietary medicinal products (CPMP). Points to consider on clinical ionvestigations of medicinal products used in the treatment of Osteoarthritis (CPMP/EWP/784/97). EMEA, Electronic Citation 1998
23. The WOMAC Knee and Hip Osteoarthritis Indices: development, validation, globalization and influence on the development of the AUSCAN Hand Osteoarthritis Indices. N Bellamy, Clin Exp Rheumatol 2005 23 5 Suppl 39 148 53 16273799
24. Viscosupplementation for the treatment of osteoarthritis of the knee. N Bellamy J Campbell V Robinson T Gee R Bourne G Wells, Cochrane Database Syst Rev 2005 2 D005321 15846754
25. OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. T Pham D van der Heijde RD Altman JJ Anderson N Bellamy M Hochberg L Simon V Strand T Woodworth M Dougados, Osteoarthritis Cartilage 2004 12 5 389 99 10.1016/j.joca.2004.02.001 15094138
26. The SF-36 in the Federal Health Survey-possibilities and requirements for application at the population level. M Radoschewski BM Bellach, Gesundheitswesen 1999 61 Spec No:S191-9 10726420